<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702076</url>
  </required_header>
  <id_info>
    <org_study_id>NL55949</org_study_id>
    <nct_id>NCT02702076</nct_id>
  </id_info>
  <brief_title>Apomorphine in Parkinson's Disease Patients With Visual Hallucinations</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised, double-blind, placebo-controlled trial will evaluate the efficacy of
      continuous apomorphine infusion compared to placebo in PD patients with visual
      hallucinations, inadequately controlled with clozapine and cholinesterase inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction Visual hallucinations occur frequently in Parkinson's disease (PD). The
      prevalence of visual hallucinations ranges from 22 to 38%, increasing after long-term
      follow-up to more than 60%. Risk factors for visual hallucinations are age, disease duration,
      and cognitive impairment. The treatment of visual hallucinations is cumbersome and options
      are limited. Only clozapine has been proven to be efficacious without deteriorating the motor
      symptoms of PD. Instead of oral dopamine agonists and rotigotine, continuous infusion of
      apomorphine is well-tolerated in PD patients with cognitive impairments and/or visual
      hallucinations. Even beneficial effect of apomorphine on visual hallucinations are suggested,
      however there is lack of a randomized controlled trial.

      The purpose of this randomised, double-blind, placebo-controlled trial is to evaluate the
      efficacy of continuous apomorphine infusion compared to placebo in PD patients with visual
      hallucinations, inadequately controlled with clozapine and cholinesterase inhibitors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression of Severity</measure>
    <time_frame>Four weeks</time_frame>
    <description>Clinical Global Impression of Severity questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement</measure>
    <time_frame>Four weeks</time_frame>
    <description>Clinical Global Impression of Improvement questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>Four weeks</time_frame>
    <description>Montreal Cognitive Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Four weeks</time_frame>
    <description>Hamilton Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Four weeks</time_frame>
    <description>Hamilton Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor symptoms</measure>
    <time_frame>Four weeks</time_frame>
    <description>Part III of Movement Disorders Society - Unified Parkinson's Disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor complications</measure>
    <time_frame>Four weeks</time_frame>
    <description>Part IV of Movement Disorders Society - Unified Parkinson's Disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleeping problems</measure>
    <time_frame>Four weeks</time_frame>
    <description>Parkinson's Disease Sleep Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric symptoms</measure>
    <time_frame>Four weeks</time_frame>
    <description>Neuropsychiatric Inventory - Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Hallucinations</measure>
    <time_frame>Four weeks</time_frame>
    <description>Dutch Visual Hallucinations Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention</measure>
    <time_frame>Four weeks</time_frame>
    <description>Reaction Time Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual perception</measure>
    <time_frame>Four weeks</time_frame>
    <description>Visual Object and Space Perception battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apathy</measure>
    <time_frame>Four weeks</time_frame>
    <description>Apathy Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Four weeks</time_frame>
    <description>Parkinson's Disease Questionnaire (shortened version)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Four weeks</time_frame>
    <description>Orthostatic blood pressure measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Four weeks</time_frame>
    <description>Occurrence of adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Hallucinations, Visual</condition>
  <arm_group>
    <arm_group_label>Apomorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be treated with continuous subcutaneous infusion of apomorphine. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator, aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will be treated with continuous subcutaneous infusion of placebo. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apomorphine</intervention_name>
    <description>Continuous subcutaneous infusion of apomorphine during waking day</description>
    <arm_group_label>Apomorphine</arm_group_label>
    <other_name>APO-go</other_name>
    <other_name>N04BC07</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Continuous subcutaneous infusion of placebo during waking day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male subjects aged ≥30;

          -  Diagnosis of established PD, defined by the Movement Disorders Society PD criteria
             (Postuma et al., 2015);

          -  Presence of visual severe hallucinations defined as more than 3 times a week (van Laar
             et al., 2010);

          -  Visual hallucinations must have developed after PD diagnosis;

          -  Visual hallucinations must have been optimally treated with reduction of dopamine
             agonists if possible, and prescription of clozapine and/or cholinesterase inhibitors
             if needed;

          -  Female subjects must complaint with a highly effective contraceptive method (oral
             hormonal contraception alone is not considered highly effective and must be used in
             combination with a barrier method) during the study, if sexually active;

          -  Subjects should be able and capable of adhering to the protocol, visit schedules, and
             medication intake according to the judgement of the investigator.

        Exclusion Criteria:

          -  Symptomatic, clinically relevant and medically uncontrolled orthostatic hypotension;

          -  Patients with a prolonged QT interval corrected for heart rate according to Bazett's
             formula (QTc) of &gt;450 ms for male and &gt;470 ms for female at screening, or history of a
             long QT syndrome;

          -  PD medication change (i.e., dopamine-agonists, amantadine, monoamine oxidase (MAO)-B
             inhibitors, anticholinergics and cholinesterase inhibitors) in last month prior to
             initiation (van Laar et al., 2010);

          -  Active psychosis or a history of significant psychosis;

          -  Any medical condition that is likely to interfere with an adequate participation in
             the study including e.g. current diagnosis of unstable epilepsy, clinically relevant
             cardiac dysfunction and/or myocardial infarction or stroke within the last 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teus van Laar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robbert Borgemeester, MD</last_name>
    <phone>+31 50 3611519</phone>
    <email>r.w.k.borgemeester@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robbert Borgemeester, MD</last_name>
      <phone>+31 (0) 50-3611519</phone>
      <email>r.w.k.borgemeester@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Robbert Borgemeester, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teus van Laar, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>van Laar T, Postma AG, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism Relat Disord. 2010 Jan;16(1):71-2. doi: 10.1016/j.parkreldis.2009.05.006. Epub 2009 Jun 12.</citation>
    <PMID>19524477</PMID>
  </results_reference>
  <results_reference>
    <citation>Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424. Review.</citation>
    <PMID>26474316</PMID>
  </results_reference>
  <results_reference>
    <citation>Fénelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010 Feb 15;289(1-2):12-7. doi: 10.1016/j.jns.2009.08.014. Epub 2009 Sep 8. Review.</citation>
    <PMID>19740486</PMID>
  </results_reference>
  <results_reference>
    <citation>Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16;75(20):1773-9. doi: 10.1212/WNL.0b013e3181fd6158. Epub 2010 Oct 20.</citation>
    <PMID>20962287</PMID>
  </results_reference>
  <results_reference>
    <citation>Gallagher DA, Parkkinen L, O'Sullivan SS, Spratt A, Shah A, Davey CC, Bremner FD, Revesz T, Williams DR, Lees AJ, Schrag A. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain. 2011 Nov;134(Pt 11):3299-309. doi: 10.1093/brain/awr225. Epub 2011 Sep 15.</citation>
    <PMID>21921019</PMID>
  </results_reference>
  <results_reference>
    <citation>Borgemeester RW, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. Parkinsonism Relat Disord. 2016 Feb;23:17-22. doi: 10.1016/j.parkreldis.2015.11.013. Epub 2015 Nov 22.</citation>
    <PMID>26709292</PMID>
  </results_reference>
  <results_reference>
    <citation>García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, Arbelo González J, Baiges Octavio J, Burguera Hernández JA, Calopa Garriga M, Campos Blanco D, Castaño García B, Carballo Cordero M, Chacón Peña J, Espino Ibáñez A, Gorospe Onisalde A, Giménez-Roldán S, Granés Ibáñez P, Hernández Vara J, Ibáñez Alonso R, Jiménez Jiménez FJ, Krupinski J, Kulisevsky Bojarsky J, Legarda Ramírez I, Lezcano García E, Martínez-Castrillo JC, Mateo González D, Miquel Rodríguez F, Mir P, Muñoz Fargas E, Obeso Inchausti J, Olivares Romero J, Olivé Plana J, Otermin Vallejo P, Pascual Sedano B, Pérez de Colosía Rama V, Pérez López-Fraile I, Planas Comes A, Puente Periz V, Rodríguez Oroz MC, Sevillano García D, Solís Pérez P, Suárez Muñoz J, Vaamonde Gamo J, Valero Merino C, Valldeoriola Serra F, Velázquez Pérez JM, Yáñez Baña R, Zamarbide Capdepon I. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord. 2008 Jun 15;23(8):1130-6. doi: 10.1002/mds.22063.</citation>
    <PMID>18442107</PMID>
  </results_reference>
  <results_reference>
    <citation>Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P, Todorova A, Naidu Y, Tluk S, Chandiramani C, Martin A, Chaudhuri KR. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197-203. doi: 10.3233/JPD-2011-11037.</citation>
    <PMID>23934921</PMID>
  </results_reference>
  <results_reference>
    <citation>Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, Henriksen T, Martin A, Calandrella D, Rizos A, Bryndum N, Glad A, Dafsari HS, Timmermann L, Ebersbach G, Kramberger MG, Samuel M, Wenzel K, Tomantschger V, Storch A, Reichmann H, Pirtosek Z, Trost M, Svenningsson P, Palhagen S, Volkmann J, Chaudhuri KR. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord. 2015 Apr;30(4):510-6. doi: 10.1002/mds.26067. Epub 2014 Nov 10.</citation>
    <PMID>25382161</PMID>
  </results_reference>
  <results_reference>
    <citation>Ellis C, Lemmens G, Parkes JD, Abbott RJ, Pye IF, Leigh PN, Chaudhuri KR. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord. 1997 Apr;3(2):103-7.</citation>
    <PMID>18591063</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Teus van Laar</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Apomorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Hallucinations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

